REPEAT: Alaska Permanent Fund Takes Stake in Denali Therapeutics

private equity

Institutional investors are plunging billions into emerging, pre-IPO biotechnology companies. San Francisco-based Denali Therapeutics, a new biotechnology company that is focused on developing effective therapies for neurodegenerative diseases, such as Alzheimer’s, ALS, and Parkinson’s, raised a Series A round of US$ 217 million from investors. Some of the founders of Denali Therapeutics are former Genentech executives and academic experts. [ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute

institutional investor investment mandates